Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
What dosimetric and technical precautions/guidelines do you follow when treating a patient with LVAD?
If target is within 5-6 cms of LVAD, what precautions do you take?
Related Questions
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
How long would you delay prostate radiation following use of a paclitaxel-eluting balloon dilator (optilume) for management of a recurrent urethral stricture after TURP?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?